After 52-Week Follow-up Study, Adalimumab Found to Have Positive Results

Apr 4, 2016 | 2 min read

This follow up study looked at the long term effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis. Patients who underwent a 52-week cycle of adalimumab experienced a 25.6% remission rate, a 43% clinical response rate, and 38% of them experienced reduced pain and inflammation.

Read More